Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB094 in Parkinson's Disease
NCT03976349Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Aug 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of hASO2 in Parkinson's disease (PD) (13 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Adverse Events and Serious Adverse Events. Started Aug 2019; status: completed.
02
Drugs
hASO2
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03976349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976349.